ARDX Ardelyx, Inc.

13.05
-0.1  -0.76%
Previous Close 13.15
Open 13.15
Price To book 2.79
Market Cap 617.28M
Shares 47,301,000
Volume 269,662
Short Ratio 4.78
Av. Daily Volume 195,300

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Onset of action trial data due 2Q 2017.
RDX227675
Hyperkalemia
Phase 3 trial initiation announced January 3, 2017.
RDX227675
Hyperkalemia
Phase 3 released February 15, 2017 - primary endpoint met. Second Phase 3 trial to be initiated mid-2017.
Tenapanor
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3 trial initiated October 2015. Second trial initiated December 2015. Data from first trial due mid 2017, with data from second trial due late 2017.
Tenapanor
Constipation-predominant irritable bowel syndrome (IBS-C)

Latest News

  1. ARDELYX, INC. Files SEC form 10-K, Annual Report
  2. Ardelyx reports 4Q loss
  3. Ardelyx reports 4Q loss
  4. Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results
  5. Blog Coverage Ardelyx Reports Positive Data for the Treatment for Hyperphosphatemia in Patients with End-Stage Renal disease
  6. Here’s What The Latest Ardelyx Inc (ARDX) Data Means For The Company Going Forward
  7. Ardelyx Says Tenapanor Did Well In Phase 3 Study
  8. Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.
  9. ARDELYX, INC. Files SEC form 8-K, Other Events
  10. Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
  11. ARDELYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial
  12. Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia
  13. Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia
  14. Ardelyx Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference
  15. Is Ardelyx Inc (ARDX) A Good Stock To Buy Right Now?
  16. ARDELYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  17. Ardelyx, Inc. :ARDX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
  18. ARDELYX, INC. Financials
  19. Edited Transcript of ARDX earnings conference call or presentation 7-Nov-16 9:05pm GMT
  20. Ardelyx Reports Third Quarter 2016 Financial Results and Recent Progress